Abstract
Leukocytapheresis (LCAP), performed with a leukocyte removal filter, was administered five times, at 1-week intervals, for 5 weeks of intensive therapy and five times, at approximately 1-month intervals, for approximately 5 months of maintenance therapy, to 13 patients with inflammatory bowel disease (IBD) diagnosed as ulcerative colitis (UC) in 8 and Crohn's disease (CD) in 5. Clinical and blood examinations showed no side effects in any of the patients. During the intensive therapy, excellent or moderate clinical response was recognized in 11 of the 13 patients (84.6%), of whom 6 had a dramatic response; the excellent or moderate clinical response continued throughout the maintenance therapy in 8 of the patients (61.5%). Flow cytometry showed that the patients who had improved generally had high values for percentages of HLADR+, HLADR+CD3+, and HLADR+CD8+ cells before the first LCAP, and that these values and the C-reactive protein levels and erythrocyte sedimentation rates had decreased to the normal range by the end of both intensive and maintenance therapy. In the patients who showed poor response, in contrast, all the above values had been at or near normal before the initial LCAP administration. The clinical improvement in the absence of any additional medical treatment suggests that LCAP has the capacity to influence the causal mechanism(s) of IBD and that IBD is strongly associated with the cell-mediated immune response.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Moertel CG, Barge JA. A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis. Ann Intern Med 1959;51:879–889.
Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Report on therapeutic trial. Br Med J 1954;2:375–378.
Truelove SC, Witts LJ. Cortisone and corticotrophin in ulcerative colitis. Br Med J 1959;1:387–394.
Mackay IR, Wall AJ, Goldstein G. Response to azathioprine in ulcerative colitis. Am J Dig Dis 1966;11:536–545.
Podolsky DK. Inflammatory bowel disease (first of two parts). N Engl J Med 1991;325:928–937.
Sawada K, Malchesky PS, Nosé Y. Available removal system: State of the art. In: Nydegger UE (ed) Therapeutic hemapheresis in the 1990s. No. 57. Current studies in hematology and blood transfusion. Basel: Karger, 1990;51–113.
Amano K, Imazu M, Ezaki H. Therapeutic on-line fiber leukocyte filtration for rheumatoid arthritis. Artif Organs 1990;14(S2):163–166.
Amano K, Ezaki H, Fujimoto K, et al. Leukapheresis for autoimmune diseases. In: Oda T (ed) Therapeutic plasmapheresis IX. Cleveland: SAO Press, 1991;423–425.
Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Report on therapeutic trial. Br Med J 1954;2:375–383.
Bockus HL, Roth JLA, Buchman E et al. Life history of non-specific ulcerative colitis; relation of prognosis to anatomical and clinical varieties. Gastroenterologia 1956;86:549–581.
Krause U, Bergman K, Norlen BJ. Crohn's disease. A clinical study based on 186 patients. Scand J Gastroenterol 1971;6:97–108.
Aoyama T, Ino Y, Ozeki M, et al. Pharmacological studies of FUT-175, nafamostat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol 1984;35:203–227.
Wahl SM, Wilder RL, Katona IM, et al. Leukapheresis in rheumatoid arthritis; association of clinical improvement with reversal of anergy. Arthritis Rheum 1983;26(9):1076–1084.
McCarthy DA, Rampton DS, Liu Y-C. Peripheral blood neutrophils in inflammatory bowel disease: Morphological evidence of in vivo activation in active disease. Clin Exp Immunol 1991;86:489–493.
Matsuura T, West GA, Youngman KR et al. Immune activation genes in inflammatory bowel disease. Gastroenterology 1993;104:448–458.
Kawanishi T, Tsuda H. Therapeutic lymphocytapheresis in rheumatoid arthritis. Comparison of leukocyte removal filter method and centrifugal method. Jpn J Artif Organs 1994;23(2):506–510.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sawada, K., Ohnishi, K., Fukui, S. et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol 30, 322–329 (1995). https://doi.org/10.1007/BF02347507
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02347507